Glaukos Co. (NYSE:GKOS – Get Free Report)’s share price gapped down before the market opened on Friday after the company announced weaker than expected quarterly earnings. The stock had previously ...

Principal Financial Group Inc. lessened its stake in shares of Glaukos Co. (NYSE:GKOS – Free Report) by 6.9% in the 4th quarter, according to its most recent 13F filing with the Securities and ...

Highlights,Rhumbline Advisers increased its position in Glaukos Corporation, reflecting sustained institutional interest.,Key ...

Glaukos reported Q4 sales of $105.5 million, surpassing estimates, while EPS missed. Analysts see strong growth potential as ...

Glaukos' fourth-quarter results showcase a strong uptick in revenues. However, continued operating loss and rising OpEx ...

Truist Financial analyst Richard Newitter maintained a Buy rating on Glaukos (GKOS – Research Report) today. The company’s shares closed ...

Wells Fargo raised the firm’s price target on Glaukos (GKOS) to $160 from $153 and keeps an Overweight rating on the shares. The firm notes ...

Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ETCompany ParticipantsChris Lewis - Vice President, ...

Glaukos Corp (GKOS) reports robust sales growth and outlines strategic initiatives for 2025, while navigating currency and ...

The results surpassed Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of 43 cents per share. The glaucoma treatments developer ...